Targeting Human Lung Adenocarcinoma with a Suppressor of Mitochondrial Superoxide Production

Nivea Dias Amoedo1,2,3, Laetitia Dard1,2,3, Saharnaz Sarlak2,3

  • 1CELLOMET, Functional Genomics Center (CGFB), Bordeaux, France.

Insights

The novel compound AOL, a mitochondrial reactive oxygen species (mtROS) suppressor, effectively inhibits lung cancer growth by reprogramming cellular proteomes and suppressing the Warburg effect. This study demonstrates AOL

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Mitochondrial reactive oxygen species (mtROS) play a crucial role in cancer cell proliferation and survival.
  • Targeting mtROS offers a potential therapeutic strategy for cancer treatment.
  • 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione (AOL) is a novel mtROS suppressor belonging to the S1QEL class.

Purpose of the Study:

  • To investigate the effects of AOL on proteome reprogramming, bioenergetics, and growth of human lung adenocarcinoma.
  • To elucidate the molecular mechanisms underlying AOL's anticancer activity.

Main Methods:

  • Cellular ROS level assessment in human lung cancer cells.
  • Analysis of proteomic changes, bioenergetics, and cell proliferation.
  • In vivo tumor growth studies in mouse models.
  • Molecular modeling for identifying AOL binding sites.

Main Results:

  • AOL reduced cellular ROS levels without affecting Complex I activity.
  • AOL demonstrated dose-dependent inhibition of lung cancer cell proliferation and reduced tumor growth in vivo.
  • AOL suppressed Warburg effect determinants and increased NDUFV1 expression, identified as an AOL binding site.
  • Proteomic analysis revealed common and drug-specific targets when compared to MitoTEMPO, another mtROS scavenger.

Conclusions:

  • AOL exhibits preclinical anticancer properties against human lung tumors.
  • AOL functions by reprogramming the cancer cell proteome, impacting REDOX and cancer signaling pathways.
  • The study highlights AOL's potential as a novel therapeutic agent for lung adenocarcinoma.